ConforMIS (NASDAQ: CFMS) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it compare to its competitors? We will compare ConforMIS to related businesses based on the strength of its valuation, dividends, earnings, risk, analyst recommendations, institutional ownership and profitability.

Risk and Volatility

ConforMIS has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, ConforMIS’s competitors have a beta of 0.47, suggesting that their average stock price is 53% less volatile than the S&P 500.

Earnings and Valuation

This table compares ConforMIS and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ConforMIS $79.90 million -$57.58 million -1.90
ConforMIS Competitors $1.67 billion $207.58 million 80.28

ConforMIS’s competitors have higher revenue and earnings than ConforMIS. ConforMIS is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

36.1% of ConforMIS shares are owned by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 9.6% of ConforMIS shares are owned by company insiders. Comparatively, 10.3% of shares of all “Medical Devices & Implants” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares ConforMIS and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ConforMIS -72.70% -76.88% -51.42%
ConforMIS Competitors -101.23% -92.70% -30.32%

Analyst Recommendations

This is a breakdown of current ratings and target prices for ConforMIS and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ConforMIS 0 3 2 0 2.40
ConforMIS Competitors 111 729 1026 10 2.50

ConforMIS currently has a consensus price target of $6.13, indicating a potential upside of 141.14%. As a group, “Medical Devices & Implants” companies have a potential upside of 37.18%. Given ConforMIS’s higher probable upside, equities analysts plainly believe ConforMIS is more favorable than its competitors.

Summary

ConforMIS competitors beat ConforMIS on 8 of the 12 factors compared.

About ConforMIS

ConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints. It offers a line of customized knee implants designed to restore the natural shape of a patient’s knee. It offers iTotal CR, which is a total knee replacement implant. Its iFit technology platform consists of three elements, including iFit Design, its algorithms and computer software that is used to design customized implants and associated single-use patient-specific instrumentation referred to as iJigs, based on computed tomography scans of the patient and to prepare a surgical plan customized for the patient (iView); iFit Printing, which is a three-dimensional printing technology used to manufacture iJigs, and iFit Just-in-Time manufacturing and delivery capabilities.

Receive News & Ratings for ConforMIS Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc and related companies with MarketBeat.com's FREE daily email newsletter.